Our molecular analyses revealed that the RORγ antagonists could strongly inhibit the expression of not only AR and AR variants but also gene programs that are associated with an aggressive subtype of PCa, including genes involved in EMT and cell growth and proliferation. This evidence concerns the gene RORC and posterior cortical atrophy.